Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

In the present study, the treatment effect on the SRI4 response in black patients indicated a positive trend, but statistical significance was not achieved.

also in 11,005 other papers

There was a trend toward an increase in SRI4 responders for belimumab versus placebo among patients with baseline SELENA–SLEDAI scores of ≤9, although this did not reach statistical significance (Figure 4 ).

also in 111,027 other papers